Palvella Therapeutics PVLA Fair Value Adjustments On Derivative Liabilities Contingent Value Right Liability
Fair Value Adjustments On Derivative Liabilities Contingent Value Right Liability at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:FairValueAdjustmentsOnDerivativeLiabilitiesContingentValueRightLiability.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's fair value adjustments on derivative liabilities contingent value right liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's fair value adjustments on derivative liabilities contingent value right liability?
- Palvella Therapeutics (PVLA) reported fair value adjustments on derivative liabilities contingent value right liability of $202K in Q1 2026.
- What does fair value adjustments on derivative liabilities contingent value right liability mean?
- This captures the periodic revaluation of derivative liabilities, specifically those related to contingent value rights or similar performance-based financial instruments. These adjustments reflect changes in the estimated probability or timing of future payouts to stakeholders. It is a critical indicator of the potential future cash obligations tied to specific corporate milestones.